AEZS
AEterna Zentaris Inc
North American company
Healthcare
Biotechnology
/
NAV Price
-
Last Traded
-
Chg
-
-
XNAS
-
Updated: -
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
This stock can be held in:
/
Company Profile
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinology and women's health.
NASDAQ:AEZS
CA0079754028
USD
Loading Comparison
Latest AEZS News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News